Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
July 24, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer’s disease (AD) - - VG-3927 achieved...
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
July 18, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
July 18, 2024 07:00 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
June 27, 2024 02:00 ET
|
Vigil Neuroscience, Inc.
- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company’s small molecule TREM2...
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024 07:40 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer’s disease ongoing;...
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024 16:05 ET
|
Vigil Neuroscience, Inc.
- Findings from ILLUMINATE Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology - - Positive interim IGNITE Phase 2 data demonstrating...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024 07:05 ET
|
Vigil Neuroscience, Inc.
– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients...
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024 07:05 ET
|
Vigil Neuroscience, Inc.
WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...